These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20935557)

  • 1. Hepatic safety and tolerability in the maraviroc clinical development program.
    Ayoub A; Alston S; Goodrich J; Heera J; Hoepelman AI; Lalezari J; Mchale M; Nelson M; van der Ryst E; Mayer H
    AIDS; 2010 Nov; 24(17):2743-50. PubMed ID: 20935557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.
    Rockstroh JK; Soriano V; Plonski F; Bansal M; Fätkenheuer G; Small CB; Asmuth DM; Pialoux G; Mukwaya G; Jagannatha S; Heera J; Pineda JA
    HIV Clin Trials; 2015; 16(2):72-80. PubMed ID: 25923596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
    Fätkenheuer G; Pozniak AL; Johnson MA; Plettenberg A; Staszewski S; Hoepelman AI; Saag MS; Goebel FD; Rockstroh JK; Dezube BJ; Jenkins TM; Medhurst C; Sullivan JF; Ridgway C; Abel S; James IT; Youle M; van der Ryst E
    Nat Med; 2005 Nov; 11(11):1170-2. PubMed ID: 16205738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
    Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug safety evaluation of maraviroc for the treatment of HIV infection.
    Wasmuth JC; Rockstroh JK; Hardy WD
    Expert Opin Drug Saf; 2012 Jan; 11(1):161-74. PubMed ID: 22118500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
    Bredeek UF; Harbour MJ
    Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
    Emmelkamp JM; Rockstroh JK
    Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maraviroc: a new CCR5 antagonist.
    Sayana S; Khanlou H
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
    MacArthur RD; Novak RM
    Clin Infect Dis; 2008 Jul; 47(2):236-41. PubMed ID: 18532888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
    Lieberman-Blum SS; Fung HB; Bandres JC
    Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.
    van Lunzen J
    Eur J Med Res; 2007 Oct; 12(9):435-40. PubMed ID: 17933725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
    Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
    J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
    Hunt JS; Romanelli F
    Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.
    Lazzarin A; Than S; Valluri SR; Heera J; Mukwaya G
    HIV Clin Trials; 2012; 13(2):83-9. PubMed ID: 22510355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with CCR5 antagonists: which patient may have a benefit?
    Mueller MC; Bogner JR
    Eur J Med Res; 2007 Oct; 12(9):441-52. PubMed ID: 17933726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.
    Meanwell NA; Kadow JF
    Curr Opin Investig Drugs; 2007 Aug; 8(8):669-81. PubMed ID: 17668369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
    Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
    Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.